LONDON, UK / ACCESSWIRE / July 20, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Johnson & Johnson (NYSE: JNJ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=JNJ, following the Company's reporting of its second quarter fiscal 2017 earnings results on July 18, 2017. The world's biggest maker of health care products increased its guidance for sales and adjusted earnings for FY17. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JNJ. With the links below you can directly download the report of your stock of interest-free of charge at:

http://protraderdaily.com/optin/?symbol=JNJ

Earnings Reviewed

Johnson & Johnson announced sales of $18.84 billion for Q2 2017, up 1.9% compared to sales of $18.48 billion in Q2 2016. The Company's operational sales grew 2.9% on a y-o-y basis, offset by negative impact of currency of 1.0%. Johnson & Johnson's sales numbers fell short of analysts' expectations of $18.9 billion.

During Q2 2017, Johnson & Johnson's domestic sales increased 1.6% to $9.73 billion. The Company's international sales increased 2.3% on a y-o-y basis to $9.11 billion, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, Johnson & Johnson's worldwide sales increased 0.5%, domestic sales fell 1.0%, and international sales rose 2.0%.

Johnson & Johnson's net earnings and diluted earnings per share for Q2 2017 were $3.83 billion and $1.40, respectively, compared to net earnings and diluted earnings per share of $4.00 billion, or $1.43 per share, for Q2 2016. The Company's reported quarter net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.8 billion. Excluding after-tax intangible amortization expense and special items, Johnson & Johnson's adjusted net earnings for Q2 2017 were $5.0 billion and adjusted diluted earnings per share were $1.83, representing increases of 3.1% and 5.2%, respectively, on a y-o-y basis. The Company's earnings numbers exceeded Wall Street's expectation of $1.79 per share.

Segment Results

During Q2 2017, Johnson & Johnson's Worldwide Consumer sales totaled $3.48 billion, up 1.7% on a y-o-y basis, consisting of an operational increase of 2.3% and a negative impact from currency of 0.6%. The segment's domestic sales increased 7.4% to $1.48 billion, while international sales fell 2.2% to $1.99 billion, which reflected an operational decrease of 1.1% and a negative currency impact of 1.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, Johnson & Johnson's worldwide sales decreased 0.8%, domestic sales increased 1.2%, and international sales decreased 2.3%.

Johnson & Johnson's worldwide pharmaceutical sales for Q2 2017, totaled $8.64, reflecting a drop of 0.2% on a y-o-y basis, with an operational increase of 1.0% and a negative impact from currency of 1.2%. The segment's domestic sales rose dropped 2.6% to $5.01 billion, while international sales rose 3.3% to $3.63 billion, which reflected an operational increase of 6.1% and a negative currency impact of 2.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 2.6% and international sales increased 5.1%.

Johnson & Johnson's Pharmaceutical Worldwide operational results were driven by new products and the strength of core products. Strong growth in new products includes DARZALEX®, for the treatment of patients with multiple myeloma and IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. During Q2 2017, Johnson & Johnson announced the completion of the acquisition of Actelion Ltd, a leading biopharmaceutical Company, for a total purchase price of approximately $30 billion in cash.

For Q2 2017, Johnson & Johnson's Worldwide Medical Devices sales grew 4.9% to $6.73 billion, which consisted of an operational increase of 5.9% and a negative currency impact of 1.0%. The segment's Domestic sales increased 6.1% to $3.23 billion, while international sales gained 3.9% to $3.50 billion, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%. The segment's reported quarter sales included the impact of the first full quarter of the recently completed acquisition of Abbott Medical Optics which contributed 5.1% to worldwide operational sales growth.

Outlook

Johnson & Johnson increased its sales guidance for FY17 to a range of $75.8 billion to $76.1 billion. The Company also raised its adjusted earnings guidance for full-year 2017 to a range of $7.12 to $7.22 per share.

Stock Performance

At the closing bell, on Wednesday, July 19, 2017, Johnson & Johnson's stock was slightly up 0.56%, ending the trading session at $135.21. A total volume of 5.29 million shares has exchanged hands. The Company's stock price rallied 11.40% in the last three months, 17.88% in the past six months, and 7.95% in the previous twelve months. Moreover, the stock surged 17.36% since the start of the year. The stock is trading at a PE ratio of 22.73 and has a dividend yield of 2.49%. The stock currently has a market cap of $365.96 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily